penicillamine has been researched along with Thrombocytopenia in 55 studies
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.
Thrombocytopenia: A subnormal level of BLOOD PLATELETS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral chelation therapy with d-penicillamine (d-PCN) has been proven to be effective in the treatment of mild-to-moderate lead poisoning." | 9.09 | Adverse effects of reduced-dose d-penicillamine in children with mild-to-moderate lead poisoning. ( Shannon, MW; Townsend, MK, 2000) |
| "Alclofenac and D-penicillamine were compared under controlled, double-blind conditions in the treatment of 35 patients with active rheumatoid arthritis over a period of 26 weeks." | 9.04 | The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis. ( Aylward, M; Holly, F; Maddock, J; Rees, P, 1975) |
| "Twenty-three patients with the chronic progressive or intermittent relapsing form of multiple sclerosis (MS) were treated with d-penicillamine over a period from 6 weeks to 12 months." | 9.04 | Penicillamine in multiple sclerosis. Therapeutic trial and design of uncontrolled pilot drug study. ( Cendrowski, W; Czlonkowska, A, 1976) |
| " No increase in elevated creatinine, direct or indirect bilirubin, thrombocytopenia or neutropenia was apparent in those treated with D-penicillamine." | 7.74 | D-Penicillamine administration and the incidence of retinopathy of prematurity. ( Alder, SC; Baer, VL; Barraza, J; Burnett, J; Christensen, RD; Horn, JT; Lambert, DK; Richards, M; Richards, SC; Schmutz, N; Wiedmeier, SE, 2007) |
| "HLA phenotype frequencies were studied in 21 rheumatoid arthritis (RA) patients with haematotoxic reactions to aurothioglucose (AuTG) or D-penicillamine (DP), 65 matched RA controls and 277 healthy controls." | 7.67 | HLA associations in aurothioglucose- and D-penicillamine-induced haematotoxic reactions in rheumatoid arthritis. ( Reekers, P; Speerstra, F; van de Putte, LB; Vandenbroucke, JP, 1985) |
| "The long term efficacy and tolerability of sulphasalazine (SASP) in the treatment of 21 patients with active classical or definite rheumatoid arthritis (RA) were examined and compared with the effects of penicillamine in a similarly active group of RA patients." | 7.67 | The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine. ( Bacon, PA; Crockson, AP; Farr, M; Tunn, E, 1984) |
| "The prevalence of eosinophilia in 66 patients with rheumatoid arthritis receiving D-penicillamine was determined in a retrospective study." | 7.67 | Eosinophilia in rheumatoid patients treated with D-penicillamine. ( Edelman, J; Maguire, KF; Owen, ET, 1984) |
| "The mechanism of D-penicillamine induced thrombocytopenia in rheumatoid arthritis was investigated by measuring platelet life-span and platelet production rate in 2 groups of rheumatoid arthritis patients treated with 250-750 mg/day D-penicillamine, 14 with a normal platelet count and 9 with thrombocytopenia (platelet count 50-130 X 10(9)/1)." | 7.67 | Thrombokinetics in patients with rheumatoid arthritis treated with D-penicillamine. ( Brooks, PM; Gallus, AS; Geddes, R; Hill, W; Tampi, R; Thomas, D, 1984) |
| " proteinuria, haematological abnormalities, stomatitis, diarrhoea and dermatitis) in rheumatoid arthritis (RA) to sodium aurothiomalate (gold) and to D-penicillamine (PA) were studied in 32 patients." | 7.67 | HLA antigens and adverse drug reactions to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. ( Bjelle, A; Dahlqvist, SR; Möller, E; Ström, H, 1985) |
| "In a retrospective cohort study we reviewed our experience using D-penicillamine in children with low-level lead poisoning (whole blood lead levels 25 to 40 micrograms/dL) to determine its efficacy and the incidence of side effects." | 7.67 | Efficacy and toxicity of D-penicillamine in low-level lead poisoning. ( Graef, J; Lovejoy, FH; Shannon, M, 1988) |
| "To assess therapeutic effect and toxicity of D-penicillamine in relation to HLA antigens, 111 consecutive patients with rheumatoid arthritis (RA) were followed for a period of 7-9 years." | 7.67 | Longterm followup of treatment with D-penicillamine for rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens. ( Ament, BJ; Feltkamp, BW; Moens, HJ; van der Korst, JK, 1987) |
| "In a 3-centre study involving 144 patients with rheumatoid arthritis (RA), a relationship between side effects from D-penicillamine and HLA antigens, allotypic markers of the IgG heavy chain (Gm) and allotypes of complement components Bf, C4A and C4B was sought." | 7.67 | Genetic markers in rheumatoid arthritis relationship to toxicity from D-penicillamine. ( Hannah, MC; Major, GA; Mathews, JD; McCluskey, J; Muirden, KD; Property, DN; Stockman, A; Tait, BD; Zilko, PJ, 1986) |
| "One hundred fourteen patients with definite or classic rheumatoid arthritis were followed prospectively between January 1976 and April 1981 to monitor their toxicity pattern to D-penicillamine." | 7.66 | Prior gold therapy does not influence the adverse effects of D-penicillamine in rheumatoid arthritis. ( Buchanan, WW; Howard-Lock, HE; Kean, WF; Lock, CJ, 1982) |
| "The difficulties encountered in administering D-penicillamine to 40 patients with rheumatoid arthritis (RA) over a six to 24 month period are recorded." | 7.66 | Difficulties in the use of D-penicillamine in the treatment of rheumatoid arthritis. ( Barraclough, D; Kincaid-Smith, P; Macdonald, I; Muirden, KD; Richter, D; Stockman, A, 1979) |
| "One hundred and one patients with rheumatoid arthritis were followed prospectively to assess the efficacy and toxicity of therapy with D-penicillamine." | 7.66 | The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis. ( Anastassiades, TP; Dwosh, IL; Ford, PM; Kean, WF; Kelly, HG, 1980) |
| "A case of a 52-year-old white woman who developed hemolytic anemia and thrombocytopenia after receiving D-penicillamine is presented." | 7.65 | Hemolytic anemia and thrombocytopenia associated with penicillamine ingestion. ( Harrison, EE; Hickman, JW, 1975) |
| "Immune thrombocytopenia is a rare complication of progressive systemic sclerosis (PSS)." | 5.28 | Progressive systemic sclerosis complicated with immune thrombocytopenia during D-penicillamine therapy. ( Kashiwagi, H; Kato, S; Kono, I; Matsui, Y; Natsuda, H; Sakauchi, M; Suzuki, H; Takemura, H; Yamane, K, 1992) |
| "Oral chelation therapy with d-penicillamine (d-PCN) has been proven to be effective in the treatment of mild-to-moderate lead poisoning." | 5.09 | Adverse effects of reduced-dose d-penicillamine in children with mild-to-moderate lead poisoning. ( Shannon, MW; Townsend, MK, 2000) |
| "Twenty-three patients with the chronic progressive or intermittent relapsing form of multiple sclerosis (MS) were treated with d-penicillamine over a period from 6 weeks to 12 months." | 5.04 | Penicillamine in multiple sclerosis. Therapeutic trial and design of uncontrolled pilot drug study. ( Cendrowski, W; Czlonkowska, A, 1976) |
| "Alclofenac and D-penicillamine were compared under controlled, double-blind conditions in the treatment of 35 patients with active rheumatoid arthritis over a period of 26 weeks." | 5.04 | The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis. ( Aylward, M; Holly, F; Maddock, J; Rees, P, 1975) |
| " No increase in elevated creatinine, direct or indirect bilirubin, thrombocytopenia or neutropenia was apparent in those treated with D-penicillamine." | 3.74 | D-Penicillamine administration and the incidence of retinopathy of prematurity. ( Alder, SC; Baer, VL; Barraza, J; Burnett, J; Christensen, RD; Horn, JT; Lambert, DK; Richards, M; Richards, SC; Schmutz, N; Wiedmeier, SE, 2007) |
| " The administration of the NO donor S-Nitroso-N-acyl-D-penicillamine (SNAP) plus ADP or LPS, significantly prevented thrombocytopenia induced by ADP and by LPS." | 3.70 | Platelet activation and modulation of the induction of nitric oxide synthase in the conscious rat. ( Doni, MG; Picunio, S; Simioni, M, 1999) |
| "The long term efficacy and tolerability of sulphasalazine (SASP) in the treatment of 21 patients with active classical or definite rheumatoid arthritis (RA) were examined and compared with the effects of penicillamine in a similarly active group of RA patients." | 3.67 | The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine. ( Bacon, PA; Crockson, AP; Farr, M; Tunn, E, 1984) |
| "The prevalence of eosinophilia in 66 patients with rheumatoid arthritis receiving D-penicillamine was determined in a retrospective study." | 3.67 | Eosinophilia in rheumatoid patients treated with D-penicillamine. ( Edelman, J; Maguire, KF; Owen, ET, 1984) |
| "The mechanism of D-penicillamine induced thrombocytopenia in rheumatoid arthritis was investigated by measuring platelet life-span and platelet production rate in 2 groups of rheumatoid arthritis patients treated with 250-750 mg/day D-penicillamine, 14 with a normal platelet count and 9 with thrombocytopenia (platelet count 50-130 X 10(9)/1)." | 3.67 | Thrombokinetics in patients with rheumatoid arthritis treated with D-penicillamine. ( Brooks, PM; Gallus, AS; Geddes, R; Hill, W; Tampi, R; Thomas, D, 1984) |
| " proteinuria, haematological abnormalities, stomatitis, diarrhoea and dermatitis) in rheumatoid arthritis (RA) to sodium aurothiomalate (gold) and to D-penicillamine (PA) were studied in 32 patients." | 3.67 | HLA antigens and adverse drug reactions to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. ( Bjelle, A; Dahlqvist, SR; Möller, E; Ström, H, 1985) |
| "In a retrospective cohort study we reviewed our experience using D-penicillamine in children with low-level lead poisoning (whole blood lead levels 25 to 40 micrograms/dL) to determine its efficacy and the incidence of side effects." | 3.67 | Efficacy and toxicity of D-penicillamine in low-level lead poisoning. ( Graef, J; Lovejoy, FH; Shannon, M, 1988) |
| "To assess therapeutic effect and toxicity of D-penicillamine in relation to HLA antigens, 111 consecutive patients with rheumatoid arthritis (RA) were followed for a period of 7-9 years." | 3.67 | Longterm followup of treatment with D-penicillamine for rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens. ( Ament, BJ; Feltkamp, BW; Moens, HJ; van der Korst, JK, 1987) |
| "In a 3-centre study involving 144 patients with rheumatoid arthritis (RA), a relationship between side effects from D-penicillamine and HLA antigens, allotypic markers of the IgG heavy chain (Gm) and allotypes of complement components Bf, C4A and C4B was sought." | 3.67 | Genetic markers in rheumatoid arthritis relationship to toxicity from D-penicillamine. ( Hannah, MC; Major, GA; Mathews, JD; McCluskey, J; Muirden, KD; Property, DN; Stockman, A; Tait, BD; Zilko, PJ, 1986) |
| "HLA phenotype frequencies were studied in 21 rheumatoid arthritis (RA) patients with haematotoxic reactions to aurothioglucose (AuTG) or D-penicillamine (DP), 65 matched RA controls and 277 healthy controls." | 3.67 | HLA associations in aurothioglucose- and D-penicillamine-induced haematotoxic reactions in rheumatoid arthritis. ( Reekers, P; Speerstra, F; van de Putte, LB; Vandenbroucke, JP, 1985) |
| "One hundred fourteen patients with definite or classic rheumatoid arthritis were followed prospectively between January 1976 and April 1981 to monitor their toxicity pattern to D-penicillamine." | 3.66 | Prior gold therapy does not influence the adverse effects of D-penicillamine in rheumatoid arthritis. ( Buchanan, WW; Howard-Lock, HE; Kean, WF; Lock, CJ, 1982) |
| "One hundred and one patients with rheumatoid arthritis were followed prospectively to assess the efficacy and toxicity of therapy with D-penicillamine." | 3.66 | The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis. ( Anastassiades, TP; Dwosh, IL; Ford, PM; Kean, WF; Kelly, HG, 1980) |
| "The difficulties encountered in administering D-penicillamine to 40 patients with rheumatoid arthritis (RA) over a six to 24 month period are recorded." | 3.66 | Difficulties in the use of D-penicillamine in the treatment of rheumatoid arthritis. ( Barraclough, D; Kincaid-Smith, P; Macdonald, I; Muirden, KD; Richter, D; Stockman, A, 1979) |
| "A case of a 52-year-old white woman who developed hemolytic anemia and thrombocytopenia after receiving D-penicillamine is presented." | 3.65 | Hemolytic anemia and thrombocytopenia associated with penicillamine ingestion. ( Harrison, EE; Hickman, JW, 1975) |
| "In a 53-year-old woman an acute allergic thrombocytopenia (acute Werlhf's disease) occurred after treatment with D-penicillamine for one month which led to death." | 3.65 | [Severe side-effects of treatment with D-penicillamine (author's transl)]. ( Hennemann, HH; Hubertus, H; Stocker, WG, 1975) |
| "Many of the adverse reactions produced by penicillamine and other compounds with an active sulfhydryl group form a distinctive pattern when viewed as a class." | 2.37 | Adverse effects profile of sulfhydryl compounds in man. ( Jaffe, IA, 1986) |
| "The aim of this study was to assess the clinical efficacy and safety of chelation treatment with penicillamine (PCA) in cross combination with sodium 2, 3-dimercapto-1-propane sulfonate (DMPS) repeatedly in patients with Wilson's disease (WD)." | 1.39 | Clinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson's disease. ( Chen, L; Fang, F; Li, XF; Liu, Y; Xu, SQ; Zhu, HY, 2013) |
| "Immune thrombocytopenia is a rare complication of progressive systemic sclerosis (PSS)." | 1.28 | Progressive systemic sclerosis complicated with immune thrombocytopenia during D-penicillamine therapy. ( Kashiwagi, H; Kato, S; Kono, I; Matsui, Y; Natsuda, H; Sakauchi, M; Suzuki, H; Takemura, H; Yamane, K, 1992) |
| " Adverse effects occurred more frequently after rapid increases in dosage." | 1.27 | The toxicity of D-penicillamine in systemic sclerosis. ( Blair, S; Medsger, TA; Steen, VD, 1986) |
| "Moderate thrombocytopenia was observed in three of the five bleeders and in two of the others." | 1.26 | Platelet function and coagulation in patients with Wilson disease. ( Bowie, JW; Goldstein, NP; Owen, CA, 1976) |
| " An overestimation of rare side-effects of drugs should not block the application of certain medicaments, however, they should be given only in such a high dosage as it is necessary." | 1.26 | [Hematotoxic lesions caused by non-steroidal antirheumatic agents]. ( Hüge, W; Stobbe, H, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 47 (85.45) | 18.7374 |
| 1990's | 3 (5.45) | 18.2507 |
| 2000's | 4 (7.27) | 29.6817 |
| 2010's | 1 (1.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, SQ | 1 |
| Li, XF | 1 |
| Zhu, HY | 1 |
| Liu, Y | 1 |
| Fang, F | 1 |
| Chen, L | 1 |
| Cocco, GA | 1 |
| Loudianos, G | 1 |
| Pes, GM | 1 |
| Tolu, F | 1 |
| Lepori, MB | 1 |
| Barrocu, M | 1 |
| Sechi, GP | 1 |
| HEINRICH, F | 1 |
| KALTENBACH, M | 1 |
| Christensen, RD | 1 |
| Alder, SC | 1 |
| Richards, SC | 1 |
| Lambert, DK | 1 |
| Schmutz, N | 1 |
| Wiedmeier, SE | 1 |
| Burnett, J | 1 |
| Baer, VL | 1 |
| Horn, JT | 1 |
| Richards, M | 1 |
| Barraza, J | 1 |
| Panayi, GS | 1 |
| Huston, G | 1 |
| Shah, RR | 1 |
| Mitchell, SC | 1 |
| Idle, JR | 1 |
| Smith, RL | 1 |
| Waring, RH | 1 |
| Farr, M | 1 |
| Tunn, E | 1 |
| Crockson, AP | 1 |
| Bacon, PA | 1 |
| Kean, WF | 2 |
| Lock, CJ | 1 |
| Howard-Lock, HE | 1 |
| Buchanan, WW | 2 |
| Dalmau Obrador, J | 1 |
| Martí-Vilalta, JL | 1 |
| Aguilar Barberá, M | 1 |
| Edelman, J | 1 |
| Maguire, KF | 1 |
| Owen, ET | 1 |
| Thomas, D | 1 |
| Gallus, AS | 1 |
| Brooks, PM | 1 |
| Tampi, R | 1 |
| Geddes, R | 1 |
| Hill, W | 1 |
| Klepach, GL | 1 |
| Wray, SH | 1 |
| Dwosh, IL | 1 |
| Anastassiades, TP | 1 |
| Ford, PM | 1 |
| Kelly, HG | 1 |
| Stobbe, H | 1 |
| Hüge, W | 1 |
| Picunio, S | 1 |
| Simioni, M | 1 |
| Doni, MG | 1 |
| Shannon, MW | 1 |
| Townsend, MK | 1 |
| Yamauchi, Y | 1 |
| Colombo, B | 1 |
| Gerloni, V | 1 |
| Harth, M | 1 |
| Hickey, JP | 1 |
| Coulter, WK | 1 |
| Thompson, JM | 1 |
| Disney, TF | 1 |
| Maddock, J | 1 |
| Rees, P | 1 |
| Holly, F | 1 |
| Aylward, M | 1 |
| Stockman, A | 2 |
| Richter, D | 1 |
| Barraclough, D | 1 |
| Muirden, KD | 3 |
| Macdonald, I | 1 |
| Kincaid-Smith, P | 1 |
| Hill, HF | 1 |
| Davis, P | 1 |
| Bleehen, SS | 1 |
| Cendrowski, W | 1 |
| Czlonkowska, A | 1 |
| Huskisson, EC | 2 |
| Olhagen, B | 1 |
| Harrison, EE | 1 |
| Hickman, JW | 1 |
| Hennemann, HH | 1 |
| Hubertus, H | 1 |
| Stocker, WG | 1 |
| Owen, CA | 1 |
| Goldstein, NP | 1 |
| Bowie, JW | 1 |
| Natsuda, H | 1 |
| Matsui, Y | 1 |
| Sakauchi, M | 1 |
| Kato, S | 1 |
| Takemura, H | 1 |
| Suzuki, H | 1 |
| Kono, I | 1 |
| Yamane, K | 1 |
| Kashiwagi, H | 1 |
| Singal, DP | 1 |
| Jaffe, IA | 1 |
| Steen, VD | 1 |
| Blair, S | 1 |
| Medsger, TA | 1 |
| Magnus, JH | 1 |
| Gran, JT | 1 |
| Mikkelsen, K | 1 |
| Nygaard, H | 1 |
| Brath, HK | 1 |
| Dahlqvist, SR | 1 |
| Ström, H | 1 |
| Bjelle, A | 1 |
| Möller, E | 1 |
| Shannon, M | 1 |
| Graef, J | 1 |
| Lovejoy, FH | 1 |
| Moens, HJ | 1 |
| Ament, BJ | 1 |
| Feltkamp, BW | 1 |
| van der Korst, JK | 1 |
| Zilko, PJ | 1 |
| Major, GA | 1 |
| Tait, BD | 1 |
| Property, DN | 1 |
| Mathews, JD | 1 |
| Hannah, MC | 1 |
| McCluskey, J | 1 |
| Speerstra, F | 1 |
| Reekers, P | 1 |
| van de Putte, LB | 1 |
| Vandenbroucke, JP | 1 |
| Stacher, A | 1 |
| Alexander, M | 1 |
| Wille, G | 1 |
| Gibson, TJ | 1 |
| Balme, HW | 1 |
| Berry, H | 1 |
| Burry, HC | 1 |
| Grahame, R | 1 |
| Hart, FD | 1 |
| Henderson, DR | 1 |
| Wojtulewski, JA | 1 |
| Werner, T | 1 |
| Weinmann, HM | 1 |
| Boudin, G | 1 |
| Pépin, B | 1 |
| Wallnöfer, H | 1 |
| Hanusch, M | 1 |
| Day, AT | 1 |
| Golding, JR | 1 |
| Lee, PN | 1 |
| Butterworth, AD | 1 |
| Camus, JP | 1 |
| Crouzet, J | 1 |
| Guillien, P | 1 |
| Benichou, C | 1 |
| Lievre, JA | 1 |
| Gordon, MH | 1 |
| Ehrlich, GE | 1 |
| Kobíková, M | 1 |
| Stáva, Z | 1 |
| Waskönig, FW | 1 |
| Meyer, W | 1 |
| Fulghum, DD | 1 |
| Katz, R | 1 |
7 reviews available for penicillamine and Thrombocytopenia
| Article | Year |
|---|---|
[Wilson's disease (hepatolenticular degeneration)].
Topics: Adolescent; Adult; Anemia, Hemolytic; Central Nervous System Diseases; Child; Combined Modality Ther | 1984 |
[D-penicillamine-induced immune deficiency].
Topics: Agranulocytosis; Antirheumatic Agents; Humans; Immunologic Deficiency Syndromes; Immunosuppressive A | 2000 |
[Penicillamine: its use in rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Eruptions; Drug Evaluation; Female; Fever; Gastrointestinal | 1979 |
D-penicillamine in the treatment of rheumatoid arthritis and progressive systemic sclerosis.
Topics: Animals; Arthritis, Rheumatoid; Chelating Agents; Collagen; Copper; Humans; Leukopenia; Nephrotic Sy | 1976 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
Adverse effects profile of sulfhydryl compounds in man.
Topics: Anemia, Aplastic; Autoimmune Diseases; Captopril; Drug Eruptions; Glomerulonephritis; Humans; Neutro | 1986 |
[10 years of penicillamine].
Topics: Cystinuria; Drug Eruptions; Gold; Hepatolenticular Degeneration; Humans; Lead Poisoning; Leukopenia; | 1966 |
12 trials available for penicillamine and Thrombocytopenia
| Article | Year |
|---|---|
Adverse effects of reduced-dose d-penicillamine in children with mild-to-moderate lead poisoning.
Topics: Adolescent; Blood Cell Count; Chelating Agents; Child; Child, Preschool; Drug Eruptions; Female; Hum | 2000 |
The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Blood Proteins; Blood Sedimentation; C-Reactive Protein; Clinical Trials as T | 1975 |
Treatment of rheumatoid arthritis with penicillamine.
Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dru | 1977 |
Penicillamine in multiple sclerosis. Therapeutic trial and design of uncontrolled pilot drug study.
Topics: Adult; Ageusia; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Dyspepsia; Erythema; Fem | 1976 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
Controlled trial of D(-)penicillamine in severe rheumatoid arthritis.
Topics: Administration, Oral; Adult; Aged; Albuminuria; Anorexia Nervosa; Arthritis, Rheumatoid; Carbonates; | 1973 |
Trial comparing D-penicillamine and gold in rheumatoid arthritis. Preliminary report.
Topics: Agglutination Tests; Arthritis, Rheumatoid; Blood Sedimentation; Clinical Trials as Topic; Feeding a | 1974 |
[Treatment of chronic hepatitis with immunosuppressive agents and D-penicillamine].
Topics: Agranulocytosis; Azathioprine; Chronic Disease; Clinical Trials as Topic; Drug Hypersensitivity; Fem | 1973 |
Penicillamine in rheumatoid disease: a long-term study.
Topics: Agranulocytosis; Arthritis, Rheumatoid; Blood Sedimentation; Body Weight; Clinical Trials as Topic; | 1974 |
[100 cases of common rheumatoid polyarthritis, treated with D-penicillamin].
Topics: Adult; Aged; Antibody Specificity; Arthritis, Rheumatoid; Clinical Trials as Topic; Copper; Dyspepsi | 1974 |
Penicillamine for treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Blood Sedimentation; Clinical Trials as Topic; Copper; Drug Evaluation; Gastr | 1974 |
Absence of toxic or therapeutic interaction between penicillamine and previously administered gold in a trial of penicillamine in rheumatoid disease.
Topics: Clinical Trials as Topic; Drug Interactions; Gold; Humans; Penicillamine; Proteinuria; Rheumatic Dis | 1974 |
37 other studies available for penicillamine and Thrombocytopenia
| Article | Year |
|---|---|
Clinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson's disease.
Topics: Administration, Oral; Adolescent; Chelating Agents; Chelation Therapy; Child; Copper; Drug Administr | 2013 |
"Acquired" hepatocerebral degeneration in a patient heterozygote carrier for a novel mutation in ATP7B gene.
Topics: Adenosine Triphosphatases; Adult; Amino Acid Substitution; Basal Ganglia; Cation Transport Proteins; | 2009 |
[WILSON'S DISEASE IN THE FORM OF A PANHEMOCYTOPENIA].
Topics: Blood; Blood Coagulation Tests; Copper; Drug Therapy; Hemorrhagic Disorders; Hepatolenticular Degene | 1965 |
D-Penicillamine administration and the incidence of retinopathy of prematurity.
Topics: Bilirubin; Chelating Agents; Creatinine; Female; Humans; Incidence; Infant, Newborn; Male; Neutropen | 2007 |
Deficient sulphoxidation status and D-penicillamine toxicity.
Topics: Arthritis, Rheumatoid; Humans; Penicillamine; Proteinuria; Sulfoxides; Thrombocytopenia | 1983 |
The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine.
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Eruptions; Drug Tolerance; Dyspepsia; Female; Humans; Male; | 1984 |
Prior gold therapy does not influence the adverse effects of D-penicillamine in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Child; Drug Eruptions; Drug Interactions; Dysgeusia; | 1982 |
Eosinophilia in rheumatoid patients treated with D-penicillamine.
Topics: Adult; Aged; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Eosinophilia; Female; Humans; | 1984 |
Thrombokinetics in patients with rheumatoid arthritis treated with D-penicillamine.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Platelets; Cell Survival; Humans; Middle Aged; Penicillami | 1984 |
Bilateral serous retinal detachment with thrombocytopenia during penicillamine therapy.
Topics: Adult; Female; Fluorescein Angiography; Fundus Oculi; Hepatolenticular Degeneration; Humans; Macula | 1981 |
The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Child; Digestive System; Dose-R | 1980 |
[Hematotoxic lesions caused by non-steroidal antirheumatic agents].
Topics: Adult; Aged; Agranulocytosis; Anemia, Aplastic; Arthritis, Rheumatoid; Aspirin; Diclofenac; Female; | 1980 |
Platelet activation and modulation of the induction of nitric oxide synthase in the conscious rat.
Topics: Adenosine Diphosphate; Animals; Blood Pressure; Enzyme Induction; Heart Rate; Iloprost; Lipopolysacc | 1999 |
Editorial: D-penicillamine in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Blood Cell Count; Drug Eruptions; Humans; Penicillamine; Proteinuria; Thrombo | 1975 |
Gold-induced thrombocytopenia.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Arthritis, Rheumatoid; Dimercaprol; Female; Gold Sodium Th | 1978 |
Difficulties in the use of D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Biopsy; Dose-Response Relationship, Drug; Female; Humans; | 1979 |
[D-penicillamine].
Topics: Arthritis, Rheumatoid; Humans; Penicillamine; Thrombocytopenia | 1976 |
[Immunosuppressive treatment of rheumatologic diseases].
Topics: Arthritis; Arthritis, Rheumatoid; Drug Evaluation; Female; Humans; Immunity, Cellular; Immunosuppres | 1976 |
Editorial: Penicillamine: more lessons from experience.
Topics: Arthritis, Rheumatoid; Blood Cell Count; Drug Hypersensitivity; Humans; Penicillamine; Proteinuria; | 1975 |
Hemolytic anemia and thrombocytopenia associated with penicillamine ingestion.
Topics: Anemia, Hemolytic; Blood Cell Count; Female; Humans; Middle Aged; Penicillamine; Prednisone; Prothro | 1975 |
[Severe side-effects of treatment with D-penicillamine (author's transl)].
Topics: Acute Disease; Adult; Arthritis, Rheumatoid; Drug Hypersensitivity; Female; Humans; Male; Middle Age | 1975 |
Platelet function and coagulation in patients with Wilson disease.
Topics: Adolescent; Adult; Blood Coagulation; Blood Platelets; Child; Female; Hemorrhage; Hepatolenticular D | 1976 |
Progressive systemic sclerosis complicated with immune thrombocytopenia during D-penicillamine therapy.
Topics: Blood Platelets; Female; Humans; Immunoglobulin G; Middle Aged; Penicillamine; Scleroderma, Systemic | 1992 |
Is there a need to reclassify adult rheumatoid arthritis?
Topics: Arthritis, Rheumatoid; Female; Genes; Genetic Predisposition to Disease; Gold; HLA-DQ Antigens; HLA- | 1990 |
The toxicity of D-penicillamine in systemic sclerosis.
Topics: Arthritis, Rheumatoid; Digestive System Diseases; Dose-Response Relationship, Drug; Drug Eruptions; | 1986 |
Toxicity to D-penicillamine in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Drug Eruptions; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; | 1987 |
HLA antigens and adverse drug reactions to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Diarrhea; Drug Eruptions; Female; Gold Sodium Thiomalate; Histoc | 1985 |
Efficacy and toxicity of D-penicillamine in low-level lead poisoning.
Topics: Adolescent; Child; Child, Preschool; Humans; Infant; Lead; Lead Poisoning; Leukopenia; Penicillamine | 1988 |
Longterm followup of treatment with D-penicillamine for rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Female; Follow-Up Studies; HLA Antigens; HLA- | 1987 |
Genetic markers in rheumatoid arthritis relationship to toxicity from D-penicillamine.
Topics: Arthritis, Rheumatoid; Disease Susceptibility; Genetic Markers; Histocompatibility Antigens Class II | 1986 |
HLA associations in aurothioglucose- and D-penicillamine-induced haematotoxic reactions in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aurothioglucose; Female; Gene Frequency; Gold; Histocompatibilit | 1985 |
[Immunosuppressive therapy in hematology].
Topics: Adrenal Cortex Hormones; Adult; Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Anemia, Myelophthis | 1972 |
[D-penicillamine therapy in liver diseases. Preliminary results in 44 cases].
Topics: Adult; Aged; Chronic Disease; Female; Hepatitis; Humans; Leukopenia; Liver Cirrhosis; Liver Diseases | 1974 |
[Possible accidents due to penicillamine during treatment of Wilson's disease].
Topics: Acute Kidney Injury; Adolescent; Adult; Child; Epilepsy; Female; Hepatolenticular Degeneration; Huma | 1972 |
[Penicillamine in the treatment of scleroderma].
Topics: Adult; Drug Evaluation; Female; Humans; Male; Middle Aged; Penicillamine; Proteinuria; Scleroderma, | 1973 |
[The basal therapy of rheumatoid arthritis with d-penicillamine (author's transl)].
Topics: Arthritis, Rheumatoid; Humans; Penicillamine; Proteinuria; Thrombocytopenia; Time Factors | 1973 |
Penicillamine for scleroderma.
Topics: Animals; Drug Hypersensitivity; Feeding and Eating Disorders; Humans; Joint Diseases; Leukopenia; Pe | 1968 |